Error Triggers Sell-off
Vertex Falls on Corrected CF Results for Kalydeco Combo
By Catherine Shaffer
Wednesday, May 30, 2012
Vertex Pharmaceuticals Inc.'s stock slid more than 10 percent Tuesday following a release of corrected clinical data for a Phase II trial of Kalydeco (ivacaftor) with VX-809, showing that only 35 percent of cystic fibrosis (CF) patients with the F508del mutation experienced an absolute improvement in lung function (FEV1) of 5 percent or more, rather than the 46 percent as reported previously.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.